161 related articles for article (PubMed ID: 29263312)
41. Deletion of β-Arrestin2 in Mice Limited Pancreatic β-Cell Expansion under Metabolic Stress through Activation of the JNK Pathway.
Lin Z; Zhao Y; Song L; Mu K; Zhang M; Liu H; Li X; Zhao J; Wang C; Jia W
Mol Med; 2016 Sep; 22():74-84. PubMed ID: 26954469
[TBL] [Abstract][Full Text] [Related]
42. Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.
Dolgikh TY; Domnikova NP; Tornuev YV; Vinogradova EV; Krinitsyna YM
Bull Exp Biol Med; 2017 Feb; 162(4):483-487. PubMed ID: 28239786
[TBL] [Abstract][Full Text] [Related]
43. Increased erythrocytic and neutrophilic progenitors in myelofibrosis with myeloid metaplasia.
Ohl S; Carsten AL; Chanana AD; Chikkappa G; Cronkite EP
Eur J Cancer (1965); 1976 Feb; 12(2):131-5. PubMed ID: 1063073
[No Abstract] [Full Text] [Related]
44. Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
Wardhana ; Datau EA; Rotty LW; Haroen H
Acta Med Indones; 2011 Oct; 43(4):252-9. PubMed ID: 22156358
[TBL] [Abstract][Full Text] [Related]
45. CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis.
Nonino A; Nascimento JM; Mascarenhas CC; Mazzeu JF; Pereira RW; Jacomo RH
Braz J Med Biol Res; 2018 Dec; 52(1):e7784. PubMed ID: 30539968
[TBL] [Abstract][Full Text] [Related]
46. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
[TBL] [Abstract][Full Text] [Related]
47. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
[TBL] [Abstract][Full Text] [Related]
48. Free fatty acid receptor 4-β-arrestin 2 pathway mediates the effects of different classes of unsaturated fatty acids in osteoclasts and osteoblasts.
Kasonga AE; Kruger MC; Coetzee M
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):281-289. PubMed ID: 30578965
[TBL] [Abstract][Full Text] [Related]
49. Molecular dissection of the human A
Storme J; Cannaert A; Van Craenenbroeck K; Stove CP
Biochem Pharmacol; 2018 Feb; 148():298-307. PubMed ID: 29309765
[TBL] [Abstract][Full Text] [Related]
50. Acute myelofibrosis--a leukemia of pluripotent stem cell. A report of three cases and review of the literature.
Amberger DM; Saleem A; Kemp BL; Truong LD
Ann Clin Lab Sci; 1990; 20(6):409-14. PubMed ID: 2073090
[TBL] [Abstract][Full Text] [Related]
51. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions.
Lapidot T
Ann N Y Acad Sci; 2001 Jun; 938():83-95. PubMed ID: 11458529
[TBL] [Abstract][Full Text] [Related]
52. Notch-Expanded Murine Hematopoietic Stem and Progenitor Cells Mitigate Death from Lethal Radiation and Convey Immune Tolerance in Mismatched Recipients.
Milano F; Merriam F; Nicoud I; Li J; Gooley TA; Heimfeld S; Imren S; Delaney C
Stem Cells Transl Med; 2017 Feb; 6(2):566-575. PubMed ID: 28191773
[TBL] [Abstract][Full Text] [Related]
53. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
54. Caspase inhibitor ZVAD-fmk facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow-bone marrow transplantation.
Imai Y; Adachi Y; Shi M; Shima C; Yanai S; Okigaki M; Yamashima T; Kaneko K; Ikehara S
Stem Cells Dev; 2010 Apr; 19(4):461-8. PubMed ID: 19686047
[TBL] [Abstract][Full Text] [Related]
55. Acute myelofibrosis in progressive systemic sclerosis. Report of a case developing during long term chlorambucil therapy and discussion of pathogenetic factors.
Gisser SD; Chung KB
Am J Med; 1979 Jul; 67(1):151-4. PubMed ID: 463908
[TBL] [Abstract][Full Text] [Related]
56. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
57. Properties of myelofibrosis-derived fibroblasts.
Castro-Malaspina H; Jhanwar SC
Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
[TBL] [Abstract][Full Text] [Related]
58. Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.
Zetterberg E; Vannucchi AM; Migliaccio AR; Vainchenker W; Tulliez M; Dickie R; Hasselbalch H; Rogers R; Palmblad J
Haematologica; 2007 May; 92(5):597-604. PubMed ID: 17488682
[TBL] [Abstract][Full Text] [Related]
59. Epigenetic modifications: new therapeutic targets in primary myelofibrosis.
Hemavathy K; Wang JC
Curr Stem Cell Res Ther; 2009 Dec; 4(4):281-6. PubMed ID: 19500065
[TBL] [Abstract][Full Text] [Related]
60. PPARγ agonists promote the resolution of myelofibrosis in preclinical models.
Lambert J; Saliba J; Calderon C; Sii-Felice K; Salma M; Edmond V; Alvarez JC; Delord M; Marty C; Plo I; Kiladjian JJ; Soler E; Vainchenker W; Villeval JL; Rousselot P; Prost S
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 33914703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
